Patent 12065476 was granted and assigned to ALPINE IMMUNE SCIENCES, INC. on August, 2024 by the United States Patent and Trademark Office.
Provided herein are immunomodulatory proteins comprising variant PD-1 polypeptides, nucleic acids encoding such proteins and engineered cells expressing such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.